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Objective: To observe the anti-tumor effect of matrine combined with cisplatin on U14
rat models of cervical cancer.
Methods: A total of 80 female Kunming rats were used to establish U14 rat models of
cervical cancer and then divided into groups I, II, III, IV, with 20 rats in each. For Group
I, the control group, injection of normal saline was given around the tumors. For Group II,
injection of 2 mg/kg cisplatin was given around the tumors. For Group III, injection of
75 mg/kg matrine was given around the tumors while the combined injection of matrine
and cisplatin was given for Group IV with the same doses as Groups II and III. The
animals were sacriﬁced 10 d after the injection and tumors were taken out for the
comparisons of tumor weights after injection and calculation of anti-tumor rates, while
thymus and spleen were taken for thymus index and spleen index. Blood in eyeball was
collected for determination of changes in serum creatinine and urea nitrogen levels.
Sections of tumor issue were prepared and morphological changes in tumor tissue cells
were observed by using immunohistochemistry technique.
Results: After injection, the thymus index and spleen index in Groups III and IV were
signiﬁcantly higher than those in Groups I and II (P < 0.05) while the two indexes in
Group II were signiﬁcantly lower than Group I (P < 0.05). The tumor weights in Groups
II and IV were signiﬁcantly smaller than those in Groups I and III (P < 0.05) with
signiﬁcantly higher anti-tumor rates than Groups I and III (P < 0.05). The serum
creatinine and urea nitrogen levels in Groups III and IV were signiﬁcantly lower than
Group II (P < 0.05) and the two indicators in Group III were signiﬁcantly lower than
those in Group IV (P < 0.05). The observation under the histological microscope showed
densely arranged tumor cells in Group I, growing as a crumby structure and diffuse
appearance, with hyperchromatic and large nuclei, and abundant cytoplasm. In the case of
Group II, it showed less tumor cells, with extensive degenerative necrosis, sparse
arrangement and karyopyknosis as well as karyoclasis. For Group III, necrosis of tumor
cells in different sizes and heterogeneous color in nuclei were observed. For Group IV,
the number of tumor cells was signiﬁcantly smaller than Groups I and III and the tumor
cells presented an appearance of crumby structure as cancer nests, with more proliferation
of connective tissue.
Conclusions: The treatment of matrine combined with cisplatin can signiﬁcantly
improve the anti-tumor effect on U14 rats with cervical cancer, which can be a new
option for the treatment for cervical cancer.ﬁliated to Taishan Medical University, Yantai
enter for Women and Children's Health, China
pen access article under the CC BY-NC-ND
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Cervical cancer is the malignant tumor in female genital
organs with high incidence worldwide, seriously affecting
women's life and health [1]. According to the statistics [2], there
are about 500000 cervical cancer patients increased every year
all around the world and around 250000 people died of cervical
cancer every year, with cervical cancer ranking the top of
lethality list of gynecological malignant diseases. The
pathogenesis of cervical cancer still remains unclear and may
be related to many factors. There have been researches
conﬁrming that human papilloma virus is the key factor in
pathogenesis of cervical cancer [3–5]. At the moment, surgery,
radiotherapy and chemotherapy are the major means in the
treatment of cervical cancer at early stage, by which the
survival time and life quality of majority of patients can be
notably prolonged and improved [6]. However, for the
patients with relapse, at late stage or without tolerance to
surgery, all the aforementioned treatments show no good
effects. Therefore, it is urgent to ﬁnd a better treatment
option. Cisplatin is the cell cycle nonspeciﬁc agent and the
most common drug extensively applied in chemotherapy,
with notable effect and serious adverse effect which creates
the least tolerance for patients [7]. Traditional Chinese
medicine is indispensible in treatment of cancer, notably
regulating the patients' immunologic function and
signiﬁcantly decreasing the toxic reaction in chemotherapy
[8]. In the present study, the anti-tumor effect of matrine
combined with cisplatin in U14 rat models of cervical cancer is
studied.
2. Materials and methods
2.1. Animal origin
A total of 80 female clean grade Kunming rats, aged 6–8 wk
and weighed (20 ± 2) g were provided by Experimental Animal
Center of Wuhan University School of Medicine and raised at
room temperature, with a free access to feed and water. All the
animal handlings in the experimental process stuck strictly to
Regulations for the Administration of Affairs concerning
Experimental Animals.
2.2. Reagents and equipments
The cervical carcinoma cell line U14 was provided by
Institute of Basic Medical Sciences, Chinese Academy of
Medical Sciences. Matrine (0.15 g/each) was purchased from
Jiangsu Kanion Pharmaceutical Co. Ltd., with national
medicine permission number of H20041496. Cisplatin
(10 mg/each) was purchased from Qilu Pharmaceutical Co.
Ltd. with national medicine permission number of
H20023460. Inverted microscope was purchased from
Olympus company, Japan. Plastic petri dish was purchased
from Costar company, USA. Low temperature super-
centrifuge, SMART CELL 5% CO2 constant temperature
incubator and constant temperature water bath were pur-
chased from Heraeus company, Germany. The electrothermal
constant-temperature dry box (DHG-9245A) was purchased
from Shanghai Yiheng Instruments Co., Ltd. The fully
automatic biochemical analyser (LX-20) was purchased from
BECKMAN-COULTER company, USA.2.3. Modeling
U14 cell lines at logarithmic phase were injected into rats'
abdominal cavity and gone through the passage for three times
until the cell concentration reached 5 × 106/mL with addition of
sterile normal saline. The subcutaneous injection of 0.2 mL U14
cell lines was conducted into the right axilla to establish U14 rat
models of cervical cancer.
2.4. Grouping and treatments
After modeling, the animals were randomly divided into
Groups I,II, III and IV, with 20 rats in each. Group I, as the
control group, received the injection of 0.2 mL normal saline
around the tumors. Group II received the injection of 2 mg/kg
cisplatin around the tumors. For Group III, the injection of
75 mg/kg matrine was performed around the tumors. In the case
of Group IV, injection of matrine combined with cisplatin was
given with the same dose as Groups II and III. All the injection
was performed continuously for 10 d.
2.5. Indexes observation
After injection of medicine, the animals were sacriﬁced and
tumors were taken out for weights of tumor, calculation of anti-
tumor rate, while thymus and spleen were taken for thymus
index and spleen index. The blood in eyeball was collected for
determination of changes in serum creatinine and urea nitrogen
levels. Sections of tumor tissue were also prepared and the
morphologic changes in tumor tissue cells were observed by
using immunohistochemistry technique.
2.6. Statistical analysis
Experimental data were expressed as mean ± SD. Compari-
son between groups was performed by using the least signiﬁcant
difference method. One-way ANOVA method was for mea-
surement data. Differences with P < 0.05 were considered as
statistically signiﬁcant.
3. Results
3.1. Comparison of thymus index, spleen index, tumor
weight and anti-tumor rate after medication
After the injection of medication, the thymus index and
spleen index in Groups III and IV were signiﬁcantly higher than
those in Groups I and II (P < 0.05) while the two indexes in
Group II were signiﬁcantly lower than Group I (P < 0.05). In
Groups II and IV, the tumor weights were signiﬁcantly lower
than those in Groups I and III (P < 0.05), and the anti-tumor
rates were signiﬁcantly higher than those in Groups I and III
(P < 0.05) (Table 1).
3.2. Comparison of serum creatinine and urea nitrogen
levels after medication
The serum creatinine and urea nitrogen levels in Groups III
and IV were signiﬁcantly lower than Group II (P < 0.05) while
those two indicators in Group III were signiﬁcantly lower than
those in Group IV (P < 0.05) (Table 2).
Table 2
Comparison of serum creatinine and urea nitrogen levels after
medication.
Groups n Creatinine Urea nitrogen
Group II 20 72.04 ± 3.95 12.14 ± 2.67
Group III 20 55.11 ± 2.89*# 6.91 ± 2.11*#
Group IV 20 58.99 ± 3.80* 8.59 ± 1.22*
*: P < 0.05 compared with Group II, #: P < 0.05 compared with Group IV.
Table 1
Comparison of thymus index, spleen index, tumor weight and anti-tumor rate after medication.
Groups n Thymus index Spleen index Tumor weight Anti-tumor rate
Group I 20 2.02 ± 0.52# 10.40 ± 1.78# 1.77 ± 0.92 –
Group II 20 0.82 ± 0.44 8.14 ± 1.32 0.79 ± 0.45 57.28
Group III 20 4.01 ± 049*# 13.01 ± 2.89*# 1.04 ± 0.64# 38.59#
Group IV 20 3.87 ± 0.25*# 12.87 ± 0.35*# 0.67 ± 0.30D* 58.22D*
*: P < 0.05 compared with Groups I, #: P < 0.05 compared with Group II, D: P < 0.05 compared with Groups III.
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The histological observation showed densely arranged tumor
cells, with a crumby structure and appearance of hyperchromatic
and large nuclei and abundant cytoplasm in Group I, small
number of tumor cells, with extensive degenerative necrosis and
sparse arrangement and karyopyknosis as well as karyoclasis in
Group II. For Group III, necrosis of tumor cells in different sizes
with heterogeneous color in nuclei was observed while for
Group IV, less tumor cells than Groups I and III, and an
appearance of crumby structure as cancer nests, with more
proliferation of connective tissue were observed (Figure 1).Figure 1. Results of histological observation in all groups (hematoxylin and e4. Discussion
Cervical cancer is the common malignant disease for women,
with high incidence in developing countries, ranking the second
in the incidence list of gynecological cancer. According to the
statistics, there are 500000 cervical cancer cases increased every
year in the world and 250000 people died of cervical cancer
every year which seriously affecting women's health. The
pathogenesis of cervical cancer still remains unclear and it is
clinically believed to be related to many factors. There are re-
searches conﬁrming that human papilloma virus plays a signif-
icant role in the pathogenesis of cervical cancer.
By far, the clinical treatments for cervical cancer have been
surgery combined with radiotherapy and chemotherapy, by
which patients can attain satisfactory efﬁcacy. However, the
traditional treatments carry unsatisfactory efﬁcacy for patients
with relapse, and cervical cancer at late stage. Therefore, it is
urgent to ﬁnd a new treatment option for patients of these kinds.
Cisplatin is the cell cycle nonspeciﬁc agent and the most com-
mon drug that is extensively applied in chemotherapy. Cisplatin
inhibits the division of tumor cells by triggering obstacles in
DNA replication [3,9–13]. Cisplatin is excreted via kidneys andosin, × 400).
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of treatment, like large dose or high frequency of usage, which
can cause damage in renal proximal tubules and even kidney
failure or patients' death in the end [14–16]. Therefore, how to
reduce the toxic effect of cisplatin in the application during
the process of treatment has been the hot issue for clinical
research. Matrine is the extraction of traditional Chinese herb
Sophora ﬂavescens with functions of clear heat and dry
dampness, and belongs to tetracyclic thiazides with molecular
weight of 266; besides the traditional medicinal functions, it
also has the functions of protecting cardiovascular system,
improving patients' immunologic function, protecting liver
along with antiviral and anti-tumor roles [4,17,18]. Experiments
conﬁrm that matrine carries inhibition effect on many kinds of
cancer cells, with wide-spectrum application and low toxicity,
and can effectively improve the patients' immunologic function
[19]. The main anti-tumor mechanisms of matrine are (1) inhi-
bition of proliferation of tumor cells, and induction of cell dif-
ferentiation and apoptosis; (2) inhibition of expression and
activity of telomerase; (3) induction of changes in DNA
methylation and cell signals; (4) decrease in activity of adher-
ence factors and migration of tumor cell inﬁltration [20]. In the
present study, combined treatment of matrine and cisplatin
was used for U14 rat models of cervical cancer and 10 d after
treatment, it is found that Groups II and IV showed
signiﬁcantly lower tumor weights and signiﬁcantly higher anti-
tumor rates than Groups I and III (P < 0.05), suggesting that
treatment of matrine combined with cisplatin displays notable
inhibition effect on tumor growth in the U14 rat models of
cervical cancer. Thymus and spleen are the most important
immune organs in human body, which can inhibit the immu-
nologic function of organisms via sorts of ways in the tumori-
genesis to make the host present the state of
immunosuppression, hence, the indexes of immune organs are
important indicators for immunologic function [21–23]. In the
present study, the thymus index and spleen index in Groups
III and IV are signiﬁcantly higher than Groups I and II
(P < 0.05) and the two indexes in Group II are signiﬁcantly
lower than Group I (P < 0.05), suggesting that treatment of
matrine combined with cisplatin can apparently reduce the
immunosuppressive reaction of U14 rats with cervical cancer,
accelerate the growth of immune organs and strengthen the
immunocompetence of the host. It also shows in the present
study that the serum creatinine and urea nitrogen levels in
Groups III and IV are signiﬁcantly lower than Group II
(P < 0.05) and the two indicators in Group III are
signiﬁcantly lower than Group IV (P < 0.05), suggesting that
treatment of matrine combined with cisplatin can signiﬁcantly
reduce the toxic damage in the process of treatment and
improve the patients' life quality. In addition, histological
observation reveals that Group IV presents signiﬁcantly less
tumor cells than Groups I and III, crumby structure as cancer
nests, more proliferation of connective tissue, suggesting that
the combined treatment of matrine and cisplatin has
synergistic effect and can improve the therapeutic effect [19].
The results of the present study indicate that the combined
treatment of matrine and cisplatin, with synergistic effect, can
notably inhibit the growth of tumor in U14 rats with cervical
cancer, signiﬁcantly improve the immunologic function of rats
and decrease the toxic reaction in process of treatment. The
combined treatment of matrine and cisplatin can be a new option
for treatment of cervical cancer.Conﬂict of interest statement
We declare that we have no conﬂict of interest.
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